The Paris Life Sciences and Technology team advised Kurma Partners and Breega on the €3.5 million fundraising of Paris-based biotech startup, Brink Therapeutics.
Using an approach combining directed evolution, metagenomic exploration and artificial intelligence, Brink Therapeutics designs enzymes capable of inserting, deleting or modifying DNA sequences with unprecedented precision, paving the way for safer and more effective gene therapies.
This seed financing round was led by investors Kurma Partners and Breega, as well as Kima Ventures, Plug and Play Ventures, and well-known business angels in the healthcare and artificial intelligence sectors.
The Goodwin team was led by Anne-Charlotte Rivière and included Charlotte Muller, Marie Fillon, Louis de Chezelles and Albana Taipi.